The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Alexander G. G. Turpie

Alexander G. G. Turpie

MD, Department of Medicine

McMaster University

E-mail:

[email]@mcmaster.ca

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Alexander G. G. Turpie, MD, Department of Medicine, McMaster University, E-mail:. 2012
  • McMaster University, Hamilton, Ontario, Canada. 2001 - 2011
  • Department of Medicine, Hamilton Health Sciences, 237 Barton Street East, Hamilton, Canada. 2002 - 2009
  • Hamilton Health Sciences Corporation--General Division, Hamilton, Canada. 2002 - 2009
  • HHSC-General Division, 237 Barton St E, Hamilton, Ontario. 2001 - 2006

References

  1. Management consensus guidance for the use of rivaroxaban - an oral, direct factor Xa inhibitor. Turpie, A.G., Kreutz, R., Llau, J., Norrving, B., Haas, S. Thromb. Haemost. (2012) [Pubmed]
  2. Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients. Ageno, W., Spyropoulos, A.C., Turpie, A.G. Thromb. Haemost. (2012) [Pubmed]
  3. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Turpie, A.G., Lassen, M.R., Eriksson, B.I., Gent, M., Berkowitz, S.D., Misselwitz, F., Bandel, T.J., Homering, M., Westermeier, T., Kakkar, A.K. Thromb. Haemost. (2011) [Pubmed]
  4. Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients. Turpie, A.G., Lensing, A.W., Fuji, T., Boyle, D.A. Blood Coagul. Fibrinolysis (2009) [Pubmed]
  5. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Turpie, A.G., Lassen, M.R., Davidson, B.L., Bauer, K.A., Gent, M., Kwong, L.M., Cushner, F.D., Lotke, P.A., Berkowitz, S.D., Bandel, T.J., Benson, A., Misselwitz, F., Fisher, W.D. Lancet (2009) [Pubmed]
  6. Direct Factor Xa and direct thrombin inhibitors: a clinical trial update. Turpie, A.G. Curr. Opin. Drug. Discov. Devel (2009) [Pubmed]
  7. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Turpie, A.G., Bauer, K.A., Davidson, B.L., Fisher, W.D., Gent, M., Huo, M.H., Sinha, U., Gretler, D.D. Thromb. Haemost. (2009) [Pubmed]
  8. New oral anticoagulants in atrial fibrillation. Turpie, A.G. Eur. Heart J. (2008) [Pubmed]
  9. The top 4 advances in antithrombotic care in the last year. Turpie, A.G. Thromb. Res. (2008) [Pubmed]
  10. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Turpie, A.G. Arterioscler. Thromb. Vasc. Biol. (2007) [Pubmed]
  11. Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison. Turpie, A.G., Bauer, K.A., Caprini, J.A., Comp, P.C., Gent, M., Muntz, J.E. J. Thromb. Haemost. (2007) [Pubmed]
  12. Extended duration of thromboprophylaxis in acutely ill medical patients: optimizing therapy?. Turpie, A.G. J. Thromb. Haemost. (2007) [Pubmed]
  13. Fondaparinux in the management of patients with ST-elevation acute myocardial infarction. Turpie, A.G. Vasc. Health. Risk. Manag (2006) [Pubmed]
  14. Prevention of venous thromboembolism in medically ill patients: a clinical update. Turpie, A.G., Leizorovicz, A. Postgrad. Med. J (2006) [Pubmed]
  15. Burden of disease: medical and economic impact of acute coronary syndromes. Turpie, A.G. Am. J. Manag. Care (2006) [Pubmed]
  16. The safety of fondaparinux for the prevention and treatment of venous thromboembolism. Turpie, A.G. Expert. Opin. Drug. Saf (2005) [Pubmed]
  17. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. Turpie, A.G., Fisher, W.D., Bauer, K.A., Kwong, L.M., Irwin, M.W., Kälebo, P., Misselwitz, F., Gent, M. J. Thromb. Haemost. (2005) [Pubmed]
  18. Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy. Turpie, A.G. Expert. Opin. Pharmacother (2004) [Pubmed]
  19. The design of venous thromboembolism prophylaxis trials: fondaparinux is definitely more effective than enoxaparin in orthopaedic surgery. Turpie, A.G. Int. J. Clin. Pract. (2004) [Pubmed]
  20. Thromboprophylaxis in medical patients: the role of low-molecular-weight heparin. Turpie, A.G., Norris, T.M. Thromb. Haemost. (2004) [Pubmed]
  21. Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points. Turpie, A.G., Bauer, K.A., Eriksson, B.I., Lassen, M.R. Chest (2004) [Pubmed]
  22. Fondaparinux, the first selective factor Xa inhibitor. Turpie, A.G., Eriksson, B.I., Lassen, M.R., Bauer, K.A. Curr. Opin. Hematol. (2003) [Pubmed]
  23. Future therapeutic directions for factor Xa inhibition in the prophylaxis and treatment of thrombotic disorders. Turpie, A.G. Am. J. Health. Syst. Pharm (2003) [Pubmed]
  24. New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies. Turpie, A.G., Eriksson, B.I., Bauer, K.A., Lassen, M.R. Chest (2003) [Pubmed]
  25. Review of enoxaparin and its clinical applications in venous and arterial thromboembolism. Turpie, A.G., Mason, J.A. Expert. Opin. Pharmacother (2002) [Pubmed]
  26. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Turpie, A.G., Bauer, K.A., Eriksson, B.I., Lassen, M.R. Lancet (2002) [Pubmed]
  27. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Turpie, A.G., Bauer, K.A., Eriksson, B.I., Lassen, M.R. Arch. Intern. Med. (2002) [Pubmed]
  28. State of the art--a journey through the world of antithrombotic therapy. Turpie, A.G. Semin. Thromb. Hemost. (2002) [Pubmed]
  29. Use of selective factor Xa inhibitors in special populations. Turpie, A.G. Am J. Orthop. (2002) [Pubmed]
  30. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery. Turpie, A.G., Eriksson, B.I., Lassen, M.R., Bauer, K.A. J. South. Orthop. Assoc (2002) [Pubmed]
  31. Low-molecular-weight heparins in the treatment of acute coronary syndromes. Turpie, A.G., Antman, E.M. Arch. Intern. Med. (2001) [Pubmed]
  32. Pentasaccharide Org31540/SR90107A clinical trials update: lessons for practice. Turpie, A.G. Am. Heart J. (2001) [Pubmed]
  33. Setting a standard for venous thromboembolism prophylaxis. Turpie, A.G. Am. J. Health. Syst. Pharm (2001) [Pubmed]
  34. Overview of the clinical results of pentasaccharide in major orthopedic surgery. Turpie, A.G. Haematologica (2001) [Pubmed]
 
WikiGenes - Universities